The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma

Proteasome inhibitors have provided a significant advance in the treatment of multiple myeloma (MM). Consequently, there is increasing interest in developing strategies to target E3 ligases, de-ubiquitinases, and/or ubiquitin receptors within the ubiquitin proteasome pathway, with an aim to achieve...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncogene
Egile Nagusiak: Crawford, Lisa J., Campbell, David C., Morgan, Jonathan J., Lawson, Michelle A., Down, Jennifer M., Chauhan, Dharminder, McAvera, Roisin M., Morris, Treen C., Hamilton, Claudia, Krishnan, Aswini, Rajalingam, Krishnaraj, Chantry, Andrew D., Irvine, Alexandra E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7329634/
https://ncbi.nlm.nih.gov/pubmed/32523091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-020-1345-x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak